Clinical trial NCT05636085: Clinical Performance of the Mainz Biomed Colorectal Cancer Screening Test for Colorectal Cancer and Advanced Adenoma
Official title: Clinical Performance of the Mainz Biomed Colorectal Cancer Screening Test for the Detection of Colorectal Cancer and Advanced Adenoma in an Average Risk Population
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Colorectal Cancer
Colorectal Neoplasms
Colorectal Polyp
Colorectal Adenoma
Lead sponsor: Mainz Biomed
Sponsor class: INDUSTRY
First posted: 2022-12-05
Enrollment: 15000
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Subjects that have been advised to have or are scheduled for a screening colonoscopy.

Brief summary: This study is to determine how the Mainz Biomed Colorectal Cancer Screening Test works when used in people aged ≥45 years of age and at an average risk of developing colorectal cancer.

Detailed description: This study is to validate the clinical performance for the Mainz Biomed Colorectal Cancer Screening Test in an average risk population aged ≥45 years of age.

Stool samples will be collected from subjects ≥45 years of age, of average risk for colon cancer, and scheduled to have a screening colonoscopy. The samples will be collected prior to colonoscopy and will be tested with the Mainz Biomed Colorectal Cancer Screening Test. The results will be compared with colonoscopy results to determine test performance.

Eligibility criteria: Inclusion Criteria:

1. Subject is any sex and ≥45 years of age
2. Subject must be advised to have or be scheduled for a screening colonoscopy
3. Subject is at average risk for colorectal cancer according to the United States Preventive Services Task Force (USPSTF) guidelines, including:

   * no prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease
   * no personal diagnosis or family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer including:

     * Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease
     * Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP)
     * Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" or "Lynch Syndrome")
     * Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome, Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Neurofibromatosis and Familial Hyperplastic Polyposis
     * Cronkhite Canada Syndrome
4. Subject can understand the study procedures and is able to provide consent to participate in the study and authorizes release of relevant protected health information through reviewing and consenting to a Health Insurance Portability and Accountability Act (HIPAA) medical release form
5. Subject is able and willing to provide stool samples within ninety (90) days before the colonoscopy procedure
6. Subject is able and willing to undergo a colonoscopy after providing a stool sample

Exclusion Criteria:

1. Subject had any precancerous findings on most recent colonoscopy.
2. Subject has a history of abnormal imaging suggesting colorectal cancer (e.g., colonography, MRI, CT, barium enema)
3. Subject has a history of any of the following cancers: oral, head and neck, lung, esophagus, gastric, biliary/liver, pancreatic, small bowel, or appendiceal
4. Subject has had a positive non-invasive screening diagnostic within the associated recommended intervals

   * High-sensitivity fecal occult blood test or fecal immunochemical test within the previous twelve (12) months
   * sDNA-FIT test within the previous thirty-six (36) months
5. Subject has had a colonoscopy in the previous nine (9) years
6. Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease
7. Indication for colonoscopy due to overt rectal bleeding (e.g., hematochezia or melena) within the previous thirty (30) days
8. Subject has any condition that in the opinion of the investigator should preclude participation in the study

Primary outcomes:
measure: Sensitivity Colorectal Cancer
timeFrame: 18 to 24 months
measure: Sensitivity Advanced Adenoma
timeFrame: 18 to 24 months
measure: Specificity
timeFrame: 18 to 24 months
Secondary outcomes:
measure: Positive predictive value and negative predictive value
timeFrame: 18 to 24 months
Other outcomes:
Locations:
Study officials:
affiliation: University of Michigan
name: Danielle Kim Turgeon, MD
role: PRINCIPAL_INVESTIGATOR
References: